Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis

Cancer Prevention Research

Volumn 5, Issue 8, 2012, Pages 1007-1014

  Nkontchou, Gisèle ^a   Aout, Mounir ^b   Mahmoudi, Amel ^a   Roulot, Dominique ^a   Bourcier, Valérie ^a   Grando Lemaire, Véronique ^a   Ganne Carrie, Nathalie ^a   Trinchet, Jean Claude ^a   Vicaut, Eric ^b   Beaugrand, Michel ^a  

^a HÔPITAL JEAN VERDIER   (France)

^b UNIVERSITÉ PARIS 13   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROPRANOLOL;

ADULT; AGED; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; ESOPHAGUS VARICES; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; THROMBOCYTE COUNT;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPRANOLOL; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; VASODILATOR AGENTS;

EID: 84866523174     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0450     Document Type: Article

References (43)

1. Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-87.
2. Braks RE, Ganne-Carrie N, Fontaine H, Paries J, Grando-Lemaire V, Beaugrand M, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis Crelated cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-53.
3. Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010;52:652-7.
4. Chuma M, Hige S, Nakanishi M, Ogawa K, Natsuizaka M, Yamamoto Y, et al. 8-Hydroxy-2′-deoxy-guanosine is a risk factor for development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol 2008;23:1431-6.
5. Mazzanti R, Messerini L, Comin CE, Fedeli L, Ganne-Carrie N, Beaugrand M. Liver angiogenesis as a risk factor for hepatocellular carcinoma development in hepatitis C virus cirrhotic patients. World J Gastroenterol 2007;13:5009-14.
6. Hassan M, Selimovic D, Ghozlan H, Abdel-kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009;49:1469-82.
7. de Mochel NS, Seronello S, Wang SH, Ito C, Zheng JX, Liang TJ, et al. Hepatocyte NAD(P)H oxidases as an endogenous source of reactive oxygen species during hepatitis C virus infection. Hepatology 2010;52:47-59.
8. García-Mediavilla MV, Sánchez-Campos S, González-Pérez P, Gómez-Gonzalo M, Majano PL, López-Cabrera M, et al. Differential contribution of hepatitis C virus NS5A and core proteins to the induction of oxidative and nitrosative stress in human hepatocyte-derived cells. J Hepatol 2005;43:606-13.
9. Karin M, Takahashi T, Kapahi P, Delhase M, Chen Y, Makris C, et al. Oxidative stress and gene expression: the AP-1 and NF-kappaB connections. Biofactors 2001;15:87-9.
10. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007;67:10823-30.
11. Pearce PC, Hawkey CM, Symons C, Olsen EG. The importance of membrane stabilization in protecting the developing rat myocardium from the actions of triac. Am J Cardiovasc Pathol 1988;2:173-9.
12. Mansuy P, Mougenot N, Ramirez-Gil JF, Bonnefont-Rousselot D, Raillecove F, Komajda M, et al. Effects of prolonged propranolol treatment on left ventricular remodelling and oxidative stress after myocardial infarction in rats. J Cardiovasc Pharmacol 2000;35: 806-13.
13. Fiskum G, Starkov A, Polster BM, Chinopoulos C. Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson's disease. Ann N Y Acad Sci 2003;991:111-9.
14. Sozzani S, Agwu DE, McCall CE, O'Flaherty JT, Schmitt JD, Kent JD, et al. Propranolol, a phosphatidate phosphohydrolase inhibitor, also inhibits protein kinase C. J Biol Chem 1992;267:20481-8.
15. Annabi B, Lachambre MP, Plouffe K, Moumdjian R, Béliveau R. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion. Pharmacol Res 2009;60:438-45.
16. Sommers Smith SK, Smith DM. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002;38:298-304.
17. Quinn PJ, Crutcher EC. The action of beta-adrenoceptor antagonists on rat heart mitochondrial function in vitro: a comparison of propranolol, timolol, and atenolol. Cardiovasc Res 1984;18:212-9.
18. Reddy DS, Singh M, Chopra K. Comparative antioxidant effects of beta-adrenoceptor blockers, calcium antagonists and U-74500A against iron-dependent lipid peroxidation in murine ventricular microsomal membranes. Methods Find Exp Clin Pharmacol 1996;18: 559-67.
19. Maziere C, Auclair M, Maziere JC. Lipophilic beta-blockers inhibit monocyte and endothelial cell-mediated modification of low density lipoproteins. Biochim Biophys Acta 1992;1126:314-8.
20. Zhang D, Ma QY, Hu HT, Zhang M. beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol Ther 2010;10:19-29.
21. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-44.
22. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 2006;66: 10357-64.
23. Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, et al. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008;15:2042-52.
24. Léauté-Labréze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-51.
25. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol 2011;29:2635-44.
26. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011;29:2645-52.
27. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med 2010;362:823-32.
28. Bruix J, Sherman M, Llovet J, Beaugrand M, Lencioni R, Burroughs A, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001;35:421-430.
29. Månsson R, Joffe MM, Sun W, Hennessy S. On the estimation and use of propensity scores in case-control and case-cohort studies. Am J Epidemiol 2007;166:332-9.
30. Software. The R Project for Statistical Computing. Wien, Austria: Institute for Statistics and Mathematics. Available from: www.r-project.org.
31. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127 (5 Suppl 1):S35-50.
32. Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al.; Portal Hypertension Collaborative Group. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009;50:923-8.
33. Jutabha R, Jensen DM, Martin P, Savides T, Han SH, Gornbein J. Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology 2005;128:870-81.
34. Lui HF, Stanley AJ, Forrest EH, Jalan R, Hislop WS, Mills PR, et al. Primary prophylaxis of variceal hemorrhage: a randomized controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology 2002;123:735-44.
35. Conn HO, Grace ND, Bosch J, Groszmann RJ, Rodés J, Wright SC, et al. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: a multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. Hepatology 1991;13:902-12.
36. Pascal JP, Cales P. Propranolol in the prevention of first upper gastrointestinal tract hemorrhage inpatients with cirrhosis of the liver and esophageal varices. N Engl J Med 1987;317:856-61.
37. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Planas R, et al.; Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61.
38. Adachi T, Nakashima S, Saji S, Nakamura T, Nozawa Y. Phospholipase D activation in hepatocyte growth factor-stimulated rat hepatocytes mediates the expressions of c-jun and c-fos: involvement of protein tyrosine kinase, protein kinase C, and Ca2+. Hepatology 1996;24: 1274-81.
39. Pai JK, Pachter JA, Weinstein IB, Bishop WR. Overexpression of protein kinase C beta 1 enhances phospholipase D activity and diacylglycerol formation in phorbol ester-stimulated rat fibroblasts. Proc Natl Acad Sci U S A 1991;88:598-602.
40. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001;61:2866-9.
41. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12:369-375.
42. Palm D, Lang K, Niggemann B, Drell TL IV, Masur K, Zaenker KS, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006;118:2744-9.
43. Goldfarb Y, Sorski L, Benish M, Levi B, Melamed R, Ben-Eliyahu S. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg 2011;253:798-810.